Yeji
AdComconf 0.85

zovegalisib — AdCom

$RLAY · Relay Therapeutics, Inc. · adults with PIK3CA mutant hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor
Event date
February 3, 2026
174 days ago
Sponsor runway
12 mo
$204.6M liquid

Evidence

“On February 3, 2026, the Company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to zovegalisib (RLY-2608) in combination with fulvestrant for the treatment of adults with PIK3CA mutant hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.”
Source: 8-K filed 2026-02-03View on EDGAR ↗0001193125-26-034422

Comparable historical adcoms· last 5 years · same event type

No comparable historical outcomes in our database yet — backfill of past readouts arrives next ingestion cycle.

Recent insider activity· ±90 days

4 insiders · 0 buys · 13 sells
Sell
2026-04-28
Catinazzo Thomas
Chief Financial Officer
972 @ $14.79$14K
Sell
2026-04-28
Rahmer Peter
See remarks
753 @ $14.79$11K
Sell
2026-04-28
Bergstrom Donald A
President, R&D
1,490 @ $14.79$22K
Sell10b5-1
2026-04-09
Catinazzo Thomas
Chief Financial Officer
1,800 @ $15.00$27K
Exercise10b5-1
2026-04-09
Catinazzo Thomas
Chief Financial Officer
1,800 @ $5.22$9K
Sell10b5-1
2026-04-07
Catinazzo Thomas
Chief Financial Officer
17,717 @ $13.01$230K
Sell10b5-1
2026-03-09
Catinazzo Thomas
Chief Financial Officer
17,717 @ $10.06$178K
Sell
2026-01-28
Rahmer Peter
See remarks
1,354 @ $8.45$11K
Sell
2026-01-28
Bergstrom Donald A
President, R&D
2,686 @ $8.45$23K
Sell
2026-01-28
Catinazzo Thomas
Chief Financial Officer
1,695 @ $8.45$14K
Sell
2026-01-27
Rahmer Peter
See remarks
11,684 @ $7.62$89K
Sell
2026-01-27
Bergstrom Donald A
President, R&D
18,895 @ $7.62$144K
Sell
2026-01-27
Catinazzo Thomas
Chief Financial Officer
13,820 @ $7.62$105K
Grant
2026-01-13
Patel Sanjiv
President and CEO
1,450,000 @ ——
Grant
2026-01-13
Bergstrom Donald A
President, R&D
575,000 @ ——
Grant
2026-01-13
Rahmer Peter
See remarks
475,000 @ ——
Grant
2026-01-13
Catinazzo Thomas
Chief Financial Officer
400,000 @ ——
Sell
2026-01-06
Patel Sanjiv
President and CEO
43,168 @ $7.82$338K
Grant
2025-12-31
Patel Sanjiv
President and CEO
994 @ $2.99$3K
Grant
2025-12-31
Rahmer Peter
See remarks
994 @ $2.99$3K
← All catalysts for $RLAY